How to Get Praluent (Alirocumab) in Nebraska

Who Qualifies for Praluent in Nebraska

Alirocumab is FDA-approved for two populations: adults with heterozygous familial hypercholesterolemia (HeFH) and adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering. The FDA prescribing information specifies use as an adjunct to diet and maximally tolerated statin therapy.

Nebraska clinicians typically follow the 2018 AHA/ACC cholesterol guidelines when deciding whether to add a PCSK9 inhibitor. These guidelines recommend considering alirocumab for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statins, or for patients with HeFH whose LDL remains significantly elevated despite statin and ezetimibe therapy. In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab reduced major adverse cardiovascular events by 15% compared with placebo in patients who had experienced an acute coronary syndrome 1 to 12 months prior (HR 0.85; 95% CI, 0.78 to 0.93). That trial also showed a 29% reduction in all-cause mortality in patients whose baseline LDL-C was 100 mg/dL or higher.

Patients with statin intolerance may also qualify. A documented trial of at least two statins with documented myalgia or elevated creatine kinase typically satisfies most Nebraska commercial payer criteria for PCSK9 inhibitor coverage.

How to Get a Prescription in Nebraska

Getting started requires a prescriber and a lipid panel. Any licensed MD, DO, NP, or PA practicing in Nebraska can write a Praluent prescription, and Nebraska's telehealth statutes permit these prescribers to evaluate and prescribe via synchronous audio-video visits without a prior in-person exam.

The clinical workflow looks like this. First, a prescriber reviews your fasting lipid panel, cardiovascular history, and current medications. Second, they confirm that you meet FDA label criteria and that your LDL-C goal has not been reached with maximally tolerated statin therapy. Third, they submit the prescription to a specialty pharmacy, along with prior authorization paperwork if your insurer requires it.

For telehealth patients in rural Nebraska counties (roughly 75 of the state's 93 counties are classified as rural by the U.S. Census Bureau), this remote pathway eliminates the need to drive hours to see a lipid specialist in Omaha or Lincoln.

Labs required before starting include a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), hepatic function tests (ALT, AST), and creatine kinase if statin intolerance is claimed. These labs must be recent, generally within 90 days, to satisfy both clinical practice and insurer documentation requirements.

Prior Authorization in Nebraska: What to Expect

Prior authorization is the single biggest barrier to accessing Praluent. Nearly every commercial plan in Nebraska requires it. The process is not optional.

Documentation typically requested includes a confirmed diagnosis of HeFH or ASCVD with ICD-10 codes (E78.01 for HeFH, specific I-codes for ASCVD subtypes), two or more consecutive lipid panels showing LDL-C above goal on maximally tolerated statin therapy, a record of statin trials and documented intolerance if applicable, and prescriber attestation that ezetimibe was tried or considered. Some plans in Nebraska also require documentation that the patient tried at least two statins at maximum doses before approving a PCSK9 inhibitor.

Turnaround time ranges from 3 to 15 business days for commercial insurers. Peer-to-peer review requests, where your prescriber speaks directly with the plan's medical director, occur in approximately 20 to 30% of initial submissions nationwide according to data from the American Medical Association's 2023 prior authorization survey. Denials can be appealed; Regeneron's MyPraluent support program provides case managers who help manage the appeals process.

Nebraska Medicaid Does Not Cover Praluent

This is the most important access detail for Medicaid-enrolled Nebraskans. Nebraska Medicaid does not currently include alirocumab on its preferred drug list. Patients enrolled in Heritage Health managed care plans administered by UnitedHealthcare, Molina, or Healthy Blue in Nebraska will find that Praluent claims are denied.

Alternatives for Medicaid patients include maximizing statin therapy with the addition of ezetimibe, which reduces LDL-C by an additional 23 to 24% beyond statin monotherapy. Bempedoic acid (Nexletol) may be covered under some Medicaid formularies in Nebraska, though coverage varies by managed care organization. Inclisiran (Leqvio), a newer siRNA-based LDL-lowering agent administered every 6 months, is another option that some plans have begun adding.

For patients with HeFH and severely elevated LDL who cannot access any PCSK9 inhibitor through insurance, Regeneron offers the Praluent MyWay copay assistance program, which can reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients. Patients without any insurance may qualify for Regeneron's patient assistance program, which provides Praluent at no cost to qualifying households.

Commercial Insurance Pathways

Most large commercial insurers operating in Nebraska, including Blue Cross Blue Shield of Nebraska, UnitedHealthcare, Aetna, and Medica, cover alirocumab as a specialty-tier drug after prior authorization. Step therapy requirements are common. The typical step-edit sequence is: maximum tolerated statin first, then statin plus ezetimibe, then PCSK9 inhibitor.

Copay costs after prior authorization approval vary widely. With a specialty-tier copay, out-of-pocket cost may range from $30 to $150 per month depending on the plan. The Praluent MyWay copay card can reduce this further for commercially insured patients, with eligible patients paying as little as $0 per fill. This card cannot be used with Medicare Part D or Medicaid.

The 2019 ACC/AHA guidelines on primary prevention introduced a cost-effectiveness threshold that initially limited PCSK9 inhibitor use, but Regeneron's 2023 list price reduction (from approximately $14,000/year to $5,850/year) substantially changed the cost-effectiveness calculus. A JAMA analysis subsequently found that at the reduced price, alirocumab met conventional willingness-to-pay thresholds of $100,000 per quality-adjusted life year for high-risk ASCVD patients.

Specialty Pharmacy and Delivery in Nebraska

Praluent is dispensed almost exclusively through specialty pharmacies. Retail pharmacies like CVS or Walgreens do not routinely stock it. In Nebraska, patients typically receive their medication through one of these channels.

Mail-order specialty pharmacy is the most common route. Accredo (Express Scripts), OptumRx Specialty, CVS Specialty, and AllianceRx Walgreens Prime all ship to Nebraska addresses. Medications arrive in temperature-controlled packaging with ice packs, and shipments typically reach Omaha, Lincoln, and Grand Island within 1 to 2 business days. More remote zip codes in the Sandhills or Panhandle may see 2 to 3 day shipping windows.

Local specialty pharmacy pickup is available at select locations in Omaha and Lincoln. Nebraska Medicine's outpatient pharmacy and Bryan Health's specialty pharmacy both dispense PCSK9 inhibitors.

503A compounding pharmacies in Nebraska are licensed and may compound alirocumab preparations, though this is uncommon given the availability of the commercial product. The Nebraska Department of Health and Human Services oversees pharmacy licensing in the state.

From prescription submission to first injection, the typical timeline runs 7 to 21 days. This breaks down to 3 to 15 days for prior authorization, 1 to 3 days for specialty pharmacy processing and benefit verification, and 1 to 3 days for shipping. Patients whose prior authorization is pre-approved or who are paying cash can receive their first shipment in as few as 3 to 5 business days.

Telehealth Prescribing for Praluent in Nebraska

Nebraska law permits synchronous telehealth visits for prescribing specialty medications including PCSK9 inhibitors. The state does not require an initial in-person visit before establishing a telehealth prescriber-patient relationship, which makes remote prescribing straightforward.

Board-certified lipidologists and cardiologists who practice via telehealth can evaluate lab work, review cardiovascular history, prescribe alirocumab, and submit prior authorization paperwork without the patient ever visiting a physical clinic. This is particularly relevant for Nebraskans living in counties without a cardiologist. According to the Association of American Medical Colleges, Nebraska has approximately 5.2 cardiologists per 100,000 residents, well below the national average, and the vast majority practice in Douglas County (Omaha) or Lancaster County (Lincoln).

Telehealth visits for Praluent typically last 15 to 25 minutes. The prescriber will review labs (which can be drawn at any Quest Diagnostics, LabCorp, or local hospital lab in Nebraska), confirm the diagnosis, and discuss injection technique. Follow-up visits to monitor LDL-C response are recommended at 4 to 8 weeks after initiation, then every 3 to 6 months, and can all be conducted via telehealth.

What to Expect After Starting Praluent

Alirocumab produces rapid LDL-C reductions. In the ODYSSEY LONG TERM trial (N=2,341), patients on 150 mg every 2 weeks achieved a 61% mean reduction in LDL-C from baseline at 24 weeks compared to placebo. The LDL-lowering effect is apparent within 2 weeks of the first injection, with maximum effect at 4 to 8 weeks.

The 75 mg every-2-week starting dose is appropriate for patients who need a 30 to 50% LDL-C reduction beyond current therapy. If LDL-C remains above goal after 4 to 8 weeks, the dose can be increased to 150 mg every 2 weeks or switched to 300 mg monthly. The monthly 300 mg pen option, approved by the FDA in 2019, requires fewer injections and may improve adherence for patients who prefer less frequent dosing.

Common injection-site reactions occur in about 7% of patients, compared to 5% with placebo. Nasopharyngeal symptoms and influenza-like illness each occur at rates of roughly 4 to 5%. Serious adverse events in ODYSSEY OUTCOMES occurred at similar rates in the alirocumab and placebo groups. Dr. Gregory Schwartz, lead investigator of ODYSSEY OUTCOMES, noted that "alirocumab was associated with a favorable safety profile over a median follow-up of 2.8 years, with no increase in neurocognitive adverse events, new-onset diabetes, or hemorrhagic stroke" in the primary trial publication.

Patients self-administer Praluent using a prefilled pen injector. The injection is subcutaneous, typically given in the thigh, abdomen, or upper arm. Each pen is single-use. Pens must be refrigerated at 36 to 46 degrees Fahrenheit but can be kept at room temperature (up to 77 degrees Fahrenheit) for a maximum of 30 days before use.

Transferring a Praluent Prescription to Nebraska

Patients relocating to Nebraska from another state can transfer their Praluent prescription. The process involves having the current prescriber or pharmacy contact the receiving Nebraska pharmacy to transfer the prescription electronically or by phone. If the patient is changing insurers as a result of the move, a new prior authorization will be required under the new plan, which resets the approval timeline.

Patients moving from a state where Medicaid covered Praluent to Nebraska should be aware that Nebraska Medicaid does not cover this drug. They will need to explore commercial insurance, employer-sponsored coverage, or the Regeneron patient assistance program as alternatives.

Specialty pharmacy accounts typically need to be re-established when changing states, as the benefit verification is tied to the patient's address and insurance plan. Contacting the specialty pharmacy 2 to 3 weeks before the move helps prevent gaps in therapy. The prescriber should provide a 90-day bridge prescription if there is any risk of a coverage gap during the transition.